Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a research report released on Sunday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other analysts have also recently commented on the stock. Cantor Fitzgerald lifted their price objective on shares of Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research note on Thursday, August 1st. HC Wainwright began coverage on shares of Vanda Pharmaceuticals in a report on Thursday, October 31st. They issued a “buy” rating and a $18.00 price target on the stock.

Vanda Pharmaceuticals Stock Down 2.0 %

Vanda Pharmaceuticals stock opened at $5.00 on Friday. The stock has a 50-day moving average price of $4.80 and a 200 day moving average price of $5.26. The company has a market capitalization of $291.55 million, a price-to-earnings ratio of -17.86 and a beta of 0.77. Vanda Pharmaceuticals has a 52 week low of $3.32 and a 52 week high of $6.75.

Institutional Investors Weigh In On Vanda Pharmaceuticals

Several hedge funds have recently bought and sold shares of VNDA. BNP Paribas Financial Markets lifted its stake in shares of Vanda Pharmaceuticals by 70.1% in the 1st quarter. BNP Paribas Financial Markets now owns 101,363 shares of the biopharmaceutical company’s stock valued at $417,000 after purchasing an additional 41,767 shares during the period. Sei Investments Co. boosted its holdings in Vanda Pharmaceuticals by 39.6% in the 1st quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock worth $2,132,000 after buying an additional 147,066 shares during the last quarter. State Board of Administration of Florida Retirement System increased its position in shares of Vanda Pharmaceuticals by 142.4% during the first quarter. State Board of Administration of Florida Retirement System now owns 56,002 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 32,902 shares in the last quarter. Acadian Asset Management LLC raised its stake in Vanda Pharmaceuticals by 4.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock valued at $9,740,000 after purchasing an additional 107,203 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in Vanda Pharmaceuticals by 18.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 2,425 shares in the last quarter. Hedge funds and other institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.